MedTrace Logo

Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors

NCT04526509 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2024-11-26

Study results available
· View outcomes & findings →

Summary

This trial will evaluate the safety and efficacy of first time in human engineered T-cell therapies, in participants with advanced tumors.

Conditions

  • Neoplasms

Interventions

DRUG

GSK3901961

GSK3901961 as an IV infusion.

DRUG

GSK3845097

GSK3845097 as an IV infusion.

DRUG

GSK4427296

GSK4427296 as an IV infusion.

DRUG

Cyclophosphamide

Cyclophosphamide will be used as lymphodepleting chemotherapy and will be administered via IV route.

DRUG

Fludarabine

Fludarabine will be used as lymphodepleting chemotherapy and will be administered via IV route.

Sponsors & Collaborators

  • Adaptimmune

    lead INDUSTRY

Principal Investigators

  • Adaptimmune Patient Enquiries · Adaptimmune

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-21
Primary Completion
2023-06-08
Completion
2023-06-08
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Canada
  • Germany
  • Netherlands
  • Sweden

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04526509 on ClinicalTrials.gov